Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the-Reference-Cited by-同舟云学术

Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the

Published:2016-06-16 Issue:19 Volume:122 Page:2941-2951
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Giebel Sebastian¹,Czyz Anna²,Ottmann Oliver³,Baron Frederic⁴,Brissot Eolia⁵,Ciceri Fabio⁶,Cornelissen Jan J.⁷,Esteve Jordi⁸,Gorin Norbert-Claude⁵,Savani Bipin⁹,Schmid Christoph¹⁰,Mohty Mohamad⁵,Nagler Arnon¹¹¹²

Affiliation:

1. Department of Bone Marrow Transplantation and Onco-Hematology; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology; Gliwice Poland

2. Department of Hematology and Bone Marrow Transplantation; Poznan University of Medical Sciences; Poznan Poland

3. Institute of Cancer and Genetics; Cardiff University School of Medicine; Cardiff United Kingdom

4. Department of Hematology, Centre Hospitalier Universitaire Sart-Tilman; University of Liege; Belgium France

5. Clinical Hematology and Cellular Therapy Department, Hospital Saint-Antoine; Assistance Publique-Hôpitaux de Paris; Paris France

6. Hematology and Bone Marrow Transplantation (BMT) Unit; San Raffaele Scientific Institute; Milan Italy

7. Department of Hematology, Erasmus MC Cancer Institute; University Medical Center; Rotterdam the Netherlands

8. Hematology Department, August Pi i Sunyer Institute for Biomedical Research; Hospital Clinic; Barcelona Spain

9. Department of Hematology and Transplantation; Vanderbilt University; Nashville Tennessee

10. Department of Hematology and Oncology, Klinikum Augsburg; Ludwig-Maximilians-Universitaet; Munich Augsburg Germany

11. Division of Hematology and Bone Marrow Transplantation; Chaim Sheba Medical Center; Tel-Hashomer Israel

12. European Society for Blood and Marrow Transplantation Acute Leukemia Working Party Office; Hospital Saint-Antoine; Paris France

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference54 articles.

1. Chromosomal abnormalities and their clinical significance in acute lymphoblastic leukemia. Third International Workshop on Chromosomes in Leukemia;Bloomfield;Cancer Res.,1983

2. Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group;Burmeister;Blood.,2008

3. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial;Moorman;Blood.,2007

4. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-results of the prospective multicenter LALA-94 trial;Dombret;Blood.,2002

5. Outcome of treatment in adults with Philadelphia chromosome-positive and/or BCR-ABL-positive acute lymphoblastic leukemia-retrospective analysis of Polish Adult Leukemia Group (PALG);Wrzesien-Kus;Ann Hematol.,2006

Cited by 149 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prévention de la rechute des leucémies aiguës et syndromes myélodysplasiques en post-allogreffe : stratégies prophylactique et préemptive (SFGM-TC);Bulletin du Cancer;2024-09

2. Predicting relapse in acute lymphoblastic leukemia;Leukemia & Lymphoma;2024-08-31

3. Comparing transplant outcomes in ALL patients after myeloablative conditioning in mismatch-related or unrelated donor settings;Bone Marrow Transplantation;2024-08-15

4. Philadelphia chromosome-like acute lymphoblastic leukemia with concomitant rearrangements of CRLF2 and ABL1: a pediatric case report;BMC Pediatrics;2024-08-10

5. Impact of the Type of Tyrosine Kinase Inhibitor (imatinib or dasatinib) Used Before allo-HCT on Outcome of Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia. A Study on Behalf of the Acute Leukemia Working Party of the EBMT;Transplantation and Cellular Therapy;2024-07